<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135226</url>
  </required_header>
  <id_info>
    <org_study_id>CTSUASCEND1</org_study_id>
    <secondary_id>60635500</secondary_id>
    <nct_id>NCT00135226</nct_id>
  </id_info>
  <brief_title>ASCEND: A Study of Cardiovascular Events iN Diabetes</brief_title>
  <official_title>A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>EPD Solutions, A Philips Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 100mg daily aspirin versus placebo and/or
      supplementation with 1 gram daily omega-3 fatty acids or placebo prevents &quot;serious vascular
      events&quot; (i.e. non-fatal heart attack, non-fatal stroke or transient ischaemic attack, or
      death from vascular causes) in patients with diabetes who are not known to have occlusive
      arterial disease and to assess the effects on serious bleeding or other adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of antiplatelet therapy (chiefly aspirin) for the secondary prevention of heart
      attacks and strokes is firmly established for many high-risk people with diagnosed arterial
      disease, and the proportional reductions in these cardiovascular events appear to be about
      one quarter, whether or not such patients have diabetes. But, most younger and middle-aged
      people with diabetes do not have manifest arterial disease - although they are still at
      significant cardiovascular risk - and yet few trials have tested aspirin in such individuals.
      As a result, there is substantial uncertainty about the role of aspirin for the prevention of
      heart attacks and strokes among apparently healthy people with diabetes, and only a small
      minority receives it.

      There is consistent evidence from observational studies of lower rates of cardiovascular
      disease (particularly cardiac and sudden death) in people with higher intakes, or higher
      blood levels, of fish oils (omega-3 fatty acids). Trials in people who have survived a heart
      attack have shown modest, but potentially worthwhile, reductions in coronary events. There
      have been, however, no large-scale trials of the use of fish oils for the prevention of
      vascular events in people without diagnosed arterial disease.

      If ASCEND can reliably demonstrate that aspirin and/or fish oils safely reduce the risk of
      cardiovascular events and deaths in people with diabetes who do not have pre-existing
      arterial disease, then this would be relevant to some tens of millions of people world-wide
      (who are currently not receiving such therapy) and might save tens of thousands of lives each
      year.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Anticipated">July 31, 2037</completion_date>
  <primary_completion_date type="Actual">March 12, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With First Occurrence of Any Serious Vascular Event (SVE)</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>The primary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 fatty acids versus placebo on the first occurrence of any &quot;Serious Vascular Event&quot; (SVE), defined as:
non-fatal myocardial infarction; or
non-fatal stroke (excluding confirmed intracranial hemorrhage) or TIA; or
vascular death excluding confirmed intracranial hemorrhage (defined as International Classification of Diseases 10th revision [ICD-10] I00-52 or I63-99, i.e. excluding subarachnoid hemorrhage [I60], intracerebral hemorrhage [I61], and other non-traumatic intracranial hemorrhage [I62]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only)</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>The primary safety assessments involve intention-to-treat comparisons among all randomized patients of allocation to aspirin versus placebo on the first occurrence of &quot;any major bleed&quot;, defined as:
any confirmed intracranial hemorrhage (including intracerebral, subarachnoid, subdural or any other intracranial hemorrhage); or
sight-threatening eye bleeding; or
any other serious bleeding episode.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Combined End-point of Serious Vascular Events (SVEs) or Revascularizations</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Secondary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 versus placebo on the first occurrence of the expanded vascular endpoint of &quot;SVE or revascularization&quot; (including coronary and non-coronary revascularizations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only)</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Secondary efficacy assessments of aspirin involve intention-to-treat comparisons during the scheduled treatment period among all randomized participants on the first occurrence of:
Any incident gastrointestinal (GI) tract cancer (i.e. any GI cancer excluding pancreas and hepatobiliary), overall and after exclusion of the first three years of follow-up.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Fatal Event: All-cause Mortality</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>'All-cause mortality' includes all recorded deaths.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Fatal Event: Coronary</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Fatal 'Coronary' events include deaths from: Acute MI and other CHD (unspecified Acute ischaemic heart disease; Atherosclerotic heart disease; Ischaemic cardiomyopathy; unspecified Chronic ischaemic heart disease).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Fatal Event: All Stroke</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Fatal 'All stroke' events include deaths from: Haemorrhagic stroke (Intracerebral haemorrhage; Subarachnoid haemorrhage); Non-haemorrhagic stroke (Cerebral infarction; Stroke not specified as haemorrhage or infarction).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Fatal Event: Other Vascular</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Fatal 'Other vascular' events include deaths from: Heart failure (excluding ischaemic cardiomyopathy); Other vascular death (excluding stroke; and Cardiac death (excluding CHD).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Fatal Event: Cancer</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Fatal 'Cancer' events include any death attributed to cancer.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Fatal Event: Respiratory</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Fatal 'Respiratory' events include any death attributed to respiratory causes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Fatal Event: Other Medical</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Fatal 'Other medical' events include deaths from: Non-vascular medical causes (excluding cancer and respiratory, including Fatal GI bleed or perforation); and deaths from Renal disease and Diabetes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Fatal Event: External Cause</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Fatal 'External cause' events include deaths from: Injury; Fracture; Self harm; and Medical and surgical complications</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Fatal Event: Unknown Cause</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Any death for which the cause is not known.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Event: Any Cancer</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Incidence of fatal or non-fatal cancers. Any cancer excludes non-fatal non-melanoma skin cancer and non-fatal recurrence of a cancer that had occurred before randomization.
A single participant may have had multiple cancers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Event: Other Gastrointestinal Cancer (Aspirin Comparison Only)</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Includes fatal and non-fatal cancers. Excludes cancers reported in the gastrointestinal tract category (see secondary outcome measure #4), and includes hepatobiliary and pancreatic cancers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Event: Respiratory Cancer</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Includes fatal and non-fatal cancers. Includes lung and larynx cancer.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Event: Genitourinary Cancer</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Includes fatal and non-fatal renal, bladder, prostate, gynaecological and other GU cancers</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Event: Hematological Cancer</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Includes fatal and non-fatal cancers. Includes leukaemia and lymphoma.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Event: Breast Cancer</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Includes fatal and non-fatal cancers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Event: Melanoma</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Includes fatal and non-fatal melanomas.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Event: Other Cancer</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Includes fatal and non-fatal cancers not included elsewhere (where the type of cancer is known).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Event: Unspecified Cancer</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Includes fatal and non-fatal cancers of unknown type.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Event: Atrial Fibrillation (Omega-3 Comparison Only)</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Includes fatal and non-fatal events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Event: Other Arrhythmia (Omega-3 Comparison Only)</measure>
    <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
    <description>Includes fatal and non-fatal events, excludes atrial fibrillation.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15480</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Aspirin + Omega-3 Ethyl Esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive 100mg of aspirin once daily and 1g of omega-3 ethyl esters once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin + Placebo Omega-3 Ethyl Esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive 100mg of aspirin once daily and placebo omega-3 ethyl esters once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Aspirin + Omega-3 Ethyl Esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive placebo aspirin once daily and 1g of omega-3 ethyl esters once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Aspirin + Placebo Omega-3 Ethyl Esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive placebo aspirin once daily and placebo omega-3 ethyl esters once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Aspirin + Omega-3 Ethyl Esters</arm_group_label>
    <arm_group_label>Aspirin + Placebo Omega-3 Ethyl Esters</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 Ethyl Esters</intervention_name>
    <arm_group_label>Aspirin + Omega-3 Ethyl Esters</arm_group_label>
    <arm_group_label>Placebo Aspirin + Omega-3 Ethyl Esters</arm_group_label>
    <other_name>n-3 fatty acid</other_name>
    <other_name>Omacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Aspirin</intervention_name>
    <arm_group_label>Placebo Aspirin + Omega-3 Ethyl Esters</arm_group_label>
    <arm_group_label>Placebo Aspirin + Placebo Omega-3 Ethyl Esters</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Omega-3 Ethyl Esters</intervention_name>
    <arm_group_label>Aspirin + Placebo Omega-3 Ethyl Esters</arm_group_label>
    <arm_group_label>Placebo Aspirin + Placebo Omega-3 Ethyl Esters</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females with type 1 or type 2 diabetes mellitus.

          -  Aged ≥ 40 years.

          -  No previous history of vascular disease.

          -  No clear contra-indication to aspirin.

          -  No other predominant life-threatening medical problem.

        Exclusion Criteria:

          -  Definite history of myocardial infarction, stroke or arterial revascularisation
             procedure.

          -  Currently prescribed aspirin, warfarin or any other blood thinning medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane M Armitage, BSc, MBBS, MRCP, FFPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trial Service Unit, University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Service Unit, University of Oxford</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ctsu.ox.ac.uk/ascend</url>
    <description>Click here for more information about ASCEND : A Study of Cardiovascular Events iN Diabetes</description>
  </link>
  <link>
    <url>https://www.nejm.org/doi/10.1056/NEJMoa1804988</url>
    <description>Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus (NEJM)</description>
  </link>
  <link>
    <url>https://www.nejm.org/doi/10.1056/NEJMoa1804989</url>
    <description>Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus (NEJM)</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 24, 2005</study_first_submitted>
  <study_first_submitted_qc>August 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2005</study_first_posted>
  <results_first_submitted>January 29, 2019</results_first_submitted>
  <results_first_submitted_qc>April 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2019</results_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Omega-3 fatty acids</keyword>
  <keyword>Primary prevention</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>n-3 fatty acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Proposals for substudies must be approved by the Steering Committee. Procedures for accessing the data for this study are available on: https://www.ndph.ox.ac.uk/about/data-access-policy.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_access_criteria>See URL</ipd_access_criteria>
    <ipd_url>https://www.ndph.ox.ac.uk/about/data-access-policy</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT00135226/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT00135226/Prot_ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were randomized between June 2005 through July 2011. Follow-up continued until March 2018.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Aspirin + Omega-3 Ethyl Esters</title>
          <description>Participants receive 100mg of aspirin once daily and 1g of omega-3 ethyl esters once daily.
Aspirin
Omega-3 ethyl esters</description>
        </group>
        <group group_id="P2">
          <title>Aspirin + Placebo Omega-3 Ethyl Esters</title>
          <description>Participants receive 100mg of aspirin once daily and placebo omega-3 ethyl esters once daily.
Aspirin
Placebo omega-3 ethyl esters</description>
        </group>
        <group group_id="P3">
          <title>Placebo Aspirin + Omega-3 Ethyl Esters</title>
          <description>Participants receive placebo aspirin once daily and 1g of omega-3 ethyl esters once daily.
Placebo aspirin
Omega-3 ethyl esters</description>
        </group>
        <group group_id="P4">
          <title>Placebo Aspirin + Placebo Omega-3 Ethyl Esters</title>
          <description>Participants receive placebo aspirin once daily and placebo omega-3 ethyl esters once daily.
Placebo aspirin
Placebo omega-3 ethyl esters</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3870"/>
                <participants group_id="P2" count="3870"/>
                <participants group_id="P3" count="3870"/>
                <participants group_id="P4" count="3870"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3836"/>
                <participants group_id="P2" count="3835"/>
                <participants group_id="P3" count="3836"/>
                <participants group_id="P4" count="3834"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aspirin + Omega-3</title>
          <description>Participants receive 100mg of aspirin once daily and 1g of omega-3 ethyl esters once daily.</description>
        </group>
        <group group_id="B2">
          <title>Aspirin + Placebo Omega-3</title>
          <description>Participants receive 100mg of aspirin once daily and placebo omega-3 ethyl esters once daily.</description>
        </group>
        <group group_id="B3">
          <title>Placebo Aspirin + Omega-3</title>
          <description>Participants receive placebo aspirin once daily and 1g of omega-3 ethyl esters once daily.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Aspirin + Placebo Omega-3</title>
          <description>Participants receive placebo aspirin once daily and placebo omega-3 ethyl esters once daily.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3870"/>
            <count group_id="B2" value="3870"/>
            <count group_id="B3" value="3870"/>
            <count group_id="B4" value="3870"/>
            <count group_id="B5" value="15480"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2257"/>
                    <measurement group_id="B2" value="2259"/>
                    <measurement group_id="B3" value="2257"/>
                    <measurement group_id="B4" value="2261"/>
                    <measurement group_id="B5" value="9034"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1613"/>
                    <measurement group_id="B2" value="1611"/>
                    <measurement group_id="B3" value="1613"/>
                    <measurement group_id="B4" value="1609"/>
                    <measurement group_id="B5" value="6446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="9.3"/>
                    <measurement group_id="B2" value="63.2" spread="9.1"/>
                    <measurement group_id="B3" value="63.3" spread="9.2"/>
                    <measurement group_id="B4" value="63.3" spread="9.2"/>
                    <measurement group_id="B5" value="63.3" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1448"/>
                    <measurement group_id="B2" value="1449"/>
                    <measurement group_id="B3" value="1450"/>
                    <measurement group_id="B4" value="1449"/>
                    <measurement group_id="B5" value="5796"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2422"/>
                    <measurement group_id="B2" value="2421"/>
                    <measurement group_id="B3" value="2420"/>
                    <measurement group_id="B4" value="2421"/>
                    <measurement group_id="B5" value="9684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnic origin</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3733"/>
                    <measurement group_id="B2" value="3734"/>
                    <measurement group_id="B3" value="3734"/>
                    <measurement group_id="B4" value="3734"/>
                    <measurement group_id="B5" value="14935"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Indian/Pakistani/Bangladeshi</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African/Caribbean</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other/unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3870"/>
                    <measurement group_id="B2" value="3870"/>
                    <measurement group_id="B3" value="3870"/>
                    <measurement group_id="B4" value="3870"/>
                    <measurement group_id="B5" value="15480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-mass index (kg/m²)</title>
          <description>The body-mass index (the weight in kilograms divided by the square of the height in meters) was based on values for weight and height that were reported by the participants.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;25</title>
                  <measurement_list>
                    <measurement group_id="B1" value="522"/>
                    <measurement group_id="B2" value="558"/>
                    <measurement group_id="B3" value="607"/>
                    <measurement group_id="B4" value="562"/>
                    <measurement group_id="B5" value="2249"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥25 to &lt;30</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1356"/>
                    <measurement group_id="B2" value="1397"/>
                    <measurement group_id="B3" value="1415"/>
                    <measurement group_id="B4" value="1361"/>
                    <measurement group_id="B5" value="5529"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥30</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1863"/>
                    <measurement group_id="B2" value="1802"/>
                    <measurement group_id="B3" value="1721"/>
                    <measurement group_id="B4" value="1815"/>
                    <measurement group_id="B5" value="7201"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="132"/>
                    <measurement group_id="B5" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-mass index (mean)</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="6.3"/>
                    <measurement group_id="B2" value="30.8" spread="6.2"/>
                    <measurement group_id="B3" value="30.5" spread="6.3"/>
                    <measurement group_id="B4" value="30.7" spread="6.3"/>
                    <measurement group_id="B5" value="30.7" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Current smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="319"/>
                    <measurement group_id="B2" value="320"/>
                    <measurement group_id="B3" value="320"/>
                    <measurement group_id="B4" value="320"/>
                    <measurement group_id="B5" value="1279"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ex-smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1764"/>
                    <measurement group_id="B2" value="1762"/>
                    <measurement group_id="B3" value="1763"/>
                    <measurement group_id="B4" value="1762"/>
                    <measurement group_id="B5" value="7051"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Never smoked</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1745"/>
                    <measurement group_id="B2" value="1744"/>
                    <measurement group_id="B3" value="1744"/>
                    <measurement group_id="B4" value="1744"/>
                    <measurement group_id="B5" value="6977"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treated hypertension</title>
          <description>Participant reported hypertension</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2384"/>
                    <measurement group_id="B2" value="2382"/>
                    <measurement group_id="B3" value="2384"/>
                    <measurement group_id="B4" value="2383"/>
                    <measurement group_id="B5" value="9533"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1459"/>
                    <measurement group_id="B2" value="1460"/>
                    <measurement group_id="B3" value="1458"/>
                    <measurement group_id="B4" value="1458"/>
                    <measurement group_id="B5" value="5835"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspirin use prior to screening</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1373"/>
                    <measurement group_id="B2" value="1367"/>
                    <measurement group_id="B3" value="1371"/>
                    <measurement group_id="B4" value="1397"/>
                    <measurement group_id="B5" value="5508"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2497"/>
                    <measurement group_id="B2" value="2503"/>
                    <measurement group_id="B3" value="2499"/>
                    <measurement group_id="B4" value="2473"/>
                    <measurement group_id="B5" value="9972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of diabetes</title>
          <description>The presence of type 2 diabetes was based on a broad clinical definition involving the age of the participant at the diagnosis of diabetes, the use of insulin within 1-year after diagnosis, and the body-mass index.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Type 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="234"/>
                    <measurement group_id="B4" value="219"/>
                    <measurement group_id="B5" value="911"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Type 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3644"/>
                    <measurement group_id="B2" value="3638"/>
                    <measurement group_id="B3" value="3636"/>
                    <measurement group_id="B4" value="3651"/>
                    <measurement group_id="B5" value="14569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes (years)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;6 yr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2172"/>
                    <measurement group_id="B2" value="2165"/>
                    <measurement group_id="B3" value="2160"/>
                    <measurement group_id="B4" value="2162"/>
                    <measurement group_id="B5" value="8659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥6 &lt;13 yr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1484"/>
                    <measurement group_id="B2" value="1492"/>
                    <measurement group_id="B3" value="1496"/>
                    <measurement group_id="B4" value="1493"/>
                    <measurement group_id="B5" value="5965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥13 yr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="214"/>
                    <measurement group_id="B4" value="215"/>
                    <measurement group_id="B5" value="856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes (years)</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="3" upper_limit="13"/>
                    <measurement group_id="B2" value="7" lower_limit="3" upper_limit="13"/>
                    <measurement group_id="B3" value="7" lower_limit="3" upper_limit="12"/>
                    <measurement group_id="B4" value="7" lower_limit="3" upper_limit="13"/>
                    <measurement group_id="B5" value="7" lower_limit="3" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure (mmHg)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;130 mmHg</title>
                  <measurement_list>
                    <measurement group_id="B1" value="849"/>
                    <measurement group_id="B2" value="845"/>
                    <measurement group_id="B3" value="846"/>
                    <measurement group_id="B4" value="854"/>
                    <measurement group_id="B5" value="3394"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥130 to &lt;140 mmHg</title>
                  <measurement_list>
                    <measurement group_id="B1" value="764"/>
                    <measurement group_id="B2" value="786"/>
                    <measurement group_id="B3" value="783"/>
                    <measurement group_id="B4" value="758"/>
                    <measurement group_id="B5" value="3091"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥140 mmHg</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1140"/>
                    <measurement group_id="B2" value="1123"/>
                    <measurement group_id="B3" value="1139"/>
                    <measurement group_id="B4" value="1153"/>
                    <measurement group_id="B5" value="4555"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1117"/>
                    <measurement group_id="B2" value="1116"/>
                    <measurement group_id="B3" value="1102"/>
                    <measurement group_id="B4" value="1105"/>
                    <measurement group_id="B5" value="4440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure (mean)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136.1" spread="15.4"/>
                    <measurement group_id="B2" value="136.1" spread="15.0"/>
                    <measurement group_id="B3" value="136.2" spread="15.3"/>
                    <measurement group_id="B4" value="136.2" spread="15.2"/>
                    <measurement group_id="B5" value="136.2" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vascular risk score</title>
          <description>We categorized the predicted 5-year risk of serious vascular event (including transient ischemic attack) without the use of aspirin or n-3 fatty acids as follows: low risk as less than 5%, moderate risk as 5% to less than 10%, and high risk as 10% or more.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Low (&lt;5%)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1567"/>
                    <measurement group_id="B2" value="1561"/>
                    <measurement group_id="B3" value="1577"/>
                    <measurement group_id="B4" value="1559"/>
                    <measurement group_id="B5" value="6264"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate (≥5%, &lt;10%)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1635"/>
                    <measurement group_id="B2" value="1659"/>
                    <measurement group_id="B3" value="1634"/>
                    <measurement group_id="B4" value="1620"/>
                    <measurement group_id="B5" value="6548"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High (≥10%)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="668"/>
                    <measurement group_id="B2" value="650"/>
                    <measurement group_id="B3" value="659"/>
                    <measurement group_id="B4" value="691"/>
                    <measurement group_id="B5" value="2668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With First Occurrence of Any Serious Vascular Event (SVE)</title>
        <description>The primary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 fatty acids versus placebo on the first occurrence of any &quot;Serious Vascular Event&quot; (SVE), defined as:
non-fatal myocardial infarction; or
non-fatal stroke (excluding confirmed intracranial hemorrhage) or TIA; or
vascular death excluding confirmed intracranial hemorrhage (defined as International Classification of Diseases 10th revision [ICD-10] I00-52 or I63-99, i.e. excluding subarachnoid hemorrhage [I60], intracerebral hemorrhage [I61], and other non-traumatic intracranial hemorrhage [I62]).</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Any Serious Vascular Event (SVE)</title>
          <description>The primary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 fatty acids versus placebo on the first occurrence of any &quot;Serious Vascular Event&quot; (SVE), defined as:
non-fatal myocardial infarction; or
non-fatal stroke (excluding confirmed intracranial hemorrhage) or TIA; or
vascular death excluding confirmed intracranial hemorrhage (defined as International Classification of Diseases 10th revision [ICD-10] I00-52 or I63-99, i.e. excluding subarachnoid hemorrhage [I60], intracerebral hemorrhage [I61], and other non-traumatic intracranial hemorrhage [I62]).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="658"/>
                    <measurement group_id="O2" value="743"/>
                    <measurement group_id="O3" value="689"/>
                    <measurement group_id="O4" value="712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Log Rank</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Log Rank</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only)</title>
        <description>The primary safety assessments involve intention-to-treat comparisons among all randomized patients of allocation to aspirin versus placebo on the first occurrence of &quot;any major bleed&quot;, defined as:
any confirmed intracranial hemorrhage (including intracerebral, subarachnoid, subdural or any other intracranial hemorrhage); or
sight-threatening eye bleeding; or
any other serious bleeding episode.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only)</title>
          <description>The primary safety assessments involve intention-to-treat comparisons among all randomized patients of allocation to aspirin versus placebo on the first occurrence of &quot;any major bleed&quot;, defined as:
any confirmed intracranial hemorrhage (including intracerebral, subarachnoid, subdural or any other intracranial hemorrhage); or
sight-threatening eye bleeding; or
any other serious bleeding episode.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314"/>
                    <measurement group_id="O2" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Log Rank</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Combined End-point of Serious Vascular Events (SVEs) or Revascularizations</title>
        <description>Secondary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 versus placebo on the first occurrence of the expanded vascular endpoint of &quot;SVE or revascularization&quot; (including coronary and non-coronary revascularizations).</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <population>A single participant may have had multiple events.</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Combined End-point of Serious Vascular Events (SVEs) or Revascularizations</title>
          <description>Secondary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 versus placebo on the first occurrence of the expanded vascular endpoint of &quot;SVE or revascularization&quot; (including coronary and non-coronary revascularizations).</description>
          <population>A single participant may have had multiple events.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="833"/>
                    <measurement group_id="O2" value="936"/>
                    <measurement group_id="O3" value="882"/>
                    <measurement group_id="O4" value="887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only)</title>
        <description>Secondary efficacy assessments of aspirin involve intention-to-treat comparisons during the scheduled treatment period among all randomized participants on the first occurrence of:
Any incident gastrointestinal (GI) tract cancer (i.e. any GI cancer excluding pancreas and hepatobiliary), overall and after exclusion of the first three years of follow-up.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <population>Participants taking aspirin</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only)</title>
          <description>Secondary efficacy assessments of aspirin involve intention-to-treat comparisons during the scheduled treatment period among all randomized participants on the first occurrence of:
Any incident gastrointestinal (GI) tract cancer (i.e. any GI cancer excluding pancreas and hepatobiliary), overall and after exclusion of the first three years of follow-up.</description>
          <population>Participants taking aspirin</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Fatal Event: All-cause Mortality</title>
        <description>'All-cause mortality' includes all recorded deaths.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatal Event: All-cause Mortality</title>
          <description>'All-cause mortality' includes all recorded deaths.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="748"/>
                    <measurement group_id="O2" value="792"/>
                    <measurement group_id="O3" value="752"/>
                    <measurement group_id="O4" value="788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Risk Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Fatal Event: Coronary</title>
        <description>Fatal 'Coronary' events include deaths from: Acute MI and other CHD (unspecified Acute ischaemic heart disease; Atherosclerotic heart disease; Ischaemic cardiomyopathy; unspecified Chronic ischaemic heart disease).</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatal Event: Coronary</title>
          <description>Fatal 'Coronary' events include deaths from: Acute MI and other CHD (unspecified Acute ischaemic heart disease; Atherosclerotic heart disease; Ischaemic cardiomyopathy; unspecified Chronic ischaemic heart disease).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Fatal Event: All Stroke</title>
        <description>Fatal 'All stroke' events include deaths from: Haemorrhagic stroke (Intracerebral haemorrhage; Subarachnoid haemorrhage); Non-haemorrhagic stroke (Cerebral infarction; Stroke not specified as haemorrhage or infarction).</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatal Event: All Stroke</title>
          <description>Fatal 'All stroke' events include deaths from: Haemorrhagic stroke (Intracerebral haemorrhage; Subarachnoid haemorrhage); Non-haemorrhagic stroke (Cerebral infarction; Stroke not specified as haemorrhage or infarction).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Fatal Event: Other Vascular</title>
        <description>Fatal 'Other vascular' events include deaths from: Heart failure (excluding ischaemic cardiomyopathy); Other vascular death (excluding stroke; and Cardiac death (excluding CHD).</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatal Event: Other Vascular</title>
          <description>Fatal 'Other vascular' events include deaths from: Heart failure (excluding ischaemic cardiomyopathy); Other vascular death (excluding stroke; and Cardiac death (excluding CHD).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Fatal Event: Cancer</title>
        <description>Fatal 'Cancer' events include any death attributed to cancer.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatal Event: Cancer</title>
          <description>Fatal 'Cancer' events include any death attributed to cancer.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="315"/>
                    <measurement group_id="O3" value="305"/>
                    <measurement group_id="O4" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Fatal Event: Respiratory</title>
        <description>Fatal 'Respiratory' events include any death attributed to respiratory causes.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatal Event: Respiratory</title>
          <description>Fatal 'Respiratory' events include any death attributed to respiratory causes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Fatal Event: Other Medical</title>
        <description>Fatal 'Other medical' events include deaths from: Non-vascular medical causes (excluding cancer and respiratory, including Fatal GI bleed or perforation); and deaths from Renal disease and Diabetes.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatal Event: Other Medical</title>
          <description>Fatal 'Other medical' events include deaths from: Non-vascular medical causes (excluding cancer and respiratory, including Fatal GI bleed or perforation); and deaths from Renal disease and Diabetes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="158"/>
                    <measurement group_id="O4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Fatal Event: External Cause</title>
        <description>Fatal 'External cause' events include deaths from: Injury; Fracture; Self harm; and Medical and surgical complications</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatal Event: External Cause</title>
          <description>Fatal 'External cause' events include deaths from: Injury; Fracture; Self harm; and Medical and surgical complications</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate ratio</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Fatal Event: Unknown Cause</title>
        <description>Any death for which the cause is not known.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatal Event: Unknown Cause</title>
          <description>Any death for which the cause is not known.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>3.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Event: Any Cancer</title>
        <description>Incidence of fatal or non-fatal cancers. Any cancer excludes non-fatal non-melanoma skin cancer and non-fatal recurrence of a cancer that had occurred before randomization.
A single participant may have had multiple cancers.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Event: Any Cancer</title>
          <description>Incidence of fatal or non-fatal cancers. Any cancer excludes non-fatal non-melanoma skin cancer and non-fatal recurrence of a cancer that had occurred before randomization.
A single participant may have had multiple cancers.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="897"/>
                    <measurement group_id="O2" value="887"/>
                    <measurement group_id="O3" value="894"/>
                    <measurement group_id="O4" value="890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Risk Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Event: Other Gastrointestinal Cancer (Aspirin Comparison Only)</title>
        <description>Includes fatal and non-fatal cancers. Excludes cancers reported in the gastrointestinal tract category (see secondary outcome measure #4), and includes hepatobiliary and pancreatic cancers.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Event: Other Gastrointestinal Cancer (Aspirin Comparison Only)</title>
          <description>Includes fatal and non-fatal cancers. Excludes cancers reported in the gastrointestinal tract category (see secondary outcome measure #4), and includes hepatobiliary and pancreatic cancers.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Event: Respiratory Cancer</title>
        <description>Includes fatal and non-fatal cancers. Includes lung and larynx cancer.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Event: Respiratory Cancer</title>
          <description>Includes fatal and non-fatal cancers. Includes lung and larynx cancer.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="104"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Event: Genitourinary Cancer</title>
        <description>Includes fatal and non-fatal renal, bladder, prostate, gynaecological and other GU cancers</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Event: Genitourinary Cancer</title>
          <description>Includes fatal and non-fatal renal, bladder, prostate, gynaecological and other GU cancers</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="294"/>
                    <measurement group_id="O3" value="323"/>
                    <measurement group_id="O4" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Event: Hematological Cancer</title>
        <description>Includes fatal and non-fatal cancers. Includes leukaemia and lymphoma.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Event: Hematological Cancer</title>
          <description>Includes fatal and non-fatal cancers. Includes leukaemia and lymphoma.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Event: Breast Cancer</title>
        <description>Includes fatal and non-fatal cancers.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Event: Breast Cancer</title>
          <description>Includes fatal and non-fatal cancers.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Event: Melanoma</title>
        <description>Includes fatal and non-fatal melanomas.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Event: Melanoma</title>
          <description>Includes fatal and non-fatal melanomas.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Event: Other Cancer</title>
        <description>Includes fatal and non-fatal cancers not included elsewhere (where the type of cancer is known).</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Event: Other Cancer</title>
          <description>Includes fatal and non-fatal cancers not included elsewhere (where the type of cancer is known).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Event: Unspecified Cancer</title>
        <description>Includes fatal and non-fatal cancers of unknown type.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aspirin</title>
            <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
          </group>
          <group group_id="O3">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O4">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Event: Unspecified Cancer</title>
          <description>Includes fatal and non-fatal cancers of unknown type.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
                <count group_id="O3" value="7740"/>
                <count group_id="O4" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Event: Atrial Fibrillation (Omega-3 Comparison Only)</title>
        <description>Includes fatal and non-fatal events.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Event: Atrial Fibrillation (Omega-3 Comparison Only)</title>
          <description>Includes fatal and non-fatal events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Event: Other Arrhythmia (Omega-3 Comparison Only)</title>
        <description>Includes fatal and non-fatal events, excludes atrial fibrillation.</description>
        <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega-3</title>
            <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo Omega-3</title>
            <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Event: Other Arrhythmia (Omega-3 Comparison Only)</title>
          <description>Includes fatal and non-fatal events, excludes atrial fibrillation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7740"/>
                <count group_id="O2" value="7740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Rate Ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Randomized treatment phase during a mean of 7.4 years</time_frame>
      <desc>Follow-up questionnaires asking about cardiovascular events and other Serious Adverse Events were sent to participants at 6-monthly intervals.
Only information about Serious Adverse Events were collected, therefore there are no Non-Serious Adverse Events to report.</desc>
      <group_list>
        <group group_id="E1">
          <title>Aspirin</title>
          <description>Group includes 3870 participants in the Aspirin+Omega-3 arm, and 3870 participants in the Aspirin+Placebo Omega-3 arm</description>
        </group>
        <group group_id="E2">
          <title>Placebo Aspirin</title>
          <description>Group includes 3870 participants in the Placebo Aspirin+Omega-3 arm, and 3870 participants in the Placebo Aspirin+Placebo Omega-3 arm</description>
        </group>
        <group group_id="E3">
          <title>Omega-3</title>
          <description>Group includes 3870 participants in the Omega-3+Aspirin arm, and 3870 participants in the Omega-3+Placebo Aspirin arm</description>
        </group>
        <group group_id="E4">
          <title>Placebo Omega-3</title>
          <description>Group includes 3870 participants in the Placebo Omega-3+Aspirin arm, and 3870 participants in the Placebo Omega-3+Placebo Aspirin arm</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="748" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="792" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="752" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="788" subjects_at_risk="7740"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5264" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="5321" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="5344" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="5241" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="156" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="173" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="784" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="824" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="812" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="796" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, familial and genetic disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" subjects_affected="511" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="457" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="486" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="482" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="664" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="635" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="671" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="628" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="240" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="231" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="247" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="224" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="134" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="127" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="859" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="804" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="847" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="816" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="484" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="479" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="488" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="475" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="906" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="965" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="935" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="936" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="201" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="175" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="248" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="256" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="265" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="239" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" subjects_affected="1320" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="1266" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="1294" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="1292" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="724" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="776" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="741" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="759" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="381" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="384" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="387" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="378" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="137" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="150" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="436" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="351" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="395" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="392" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="131" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="167" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social circumstances</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" subjects_affected="2916" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="2990" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="2990" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="2916" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="7740"/>
                <counts group_id="E2" subjects_affected="213" subjects_at_risk="7740"/>
                <counts group_id="E3" subjects_affected="194" subjects_at_risk="7740"/>
                <counts group_id="E4" subjects_affected="211" subjects_at_risk="7740"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Jane Armitage</name_or_title>
      <organization>Nuffield Department of Population Health</organization>
      <phone>+44 (0)1865 743743</phone>
      <email>ascend@ndph.ox.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

